【摘要】 目的:探讨血浆髓过氧化物酶(MPO)在急性冠脉综合征(ACS)中的临床意义。方法:分别测定ACS(54例)、稳定型心绞痛(SAP,54例)和对照组(54例)3组患者的血浆MPO、血清高敏C反应蛋白(hsCRP)、肌钙蛋白I(cTnI)浓度,比较各组的差异;所有患者常规治疗,随访半年,记录心脏事件。结果:ACS组血浆MPO浓度明显高于SAP组和对照组患者(P<0.01),SAP组与对照组之间差异无统计学意义(P=0.74);ACS组患者血浆MPO与hsCRP,cTnI及心血管传统危险因素无相关性,多元logistic回归分析发现血浆MPO、空腹血糖和性别是ACS诊断的影响因素;高浓度血浆MPO患者心脏事件发生率较高。结论:血浆MPO可能是ACS的生化标志物之一,可预报心脏事件的发生。更多还原

【Abstract】 Objective To determine the diagnostic value and efficacy for risk stratification of myeloperoxidase (MPO) levels in patients with acute coronary syndrome (ACS). Methods One hundred and sixty-two patients were enrolled in this study. All patients underwent coronary angiography. They were divided into 3 groups: ACS group (n= 54), SAP group (n=54) and control group (n=54). Blood samples were taken from the artery before angiography in all patients and the concentrations of MPO,hsCRP and cTnI were measured. Each subject was asked details of history of hypertension, hyperlipidemia, diabetes and smoking habits. The efficacy of therapy, the cardiovascular events (myocardial infarction, the need for revascularization, or death) were recorded after 6 months of follow-up.Results The plasma MPO level in ACS group (30.98ng/mL) was significantly higher than those in the SAP group (14.67ng/mL) and the control group(14.23ng/mL)(P<0.01), and the plasma MPO levels in patients of the SAP group and the control group were not significantly different (P= 0.74). There was no obvious correlation between the levels of plasma MPO and the serum levels of cTnI, hsCRP,the prevalence of the 4 major risk factors for CHD. Multivariate logistic regression analysis showed that plasma MPO level, free plasma glucose and sex were the significant variables. The risk for subsequent cardiovascular events was higher in the patients with elevated level of MPO. Conclusion Plasma MPO may be a new risk biomarker for ACS and may predict the incidence of subsequent cardiovascular events.更多还原